牛牛AI助理已提取核心訊息
On February 14, 2024, ZyVersa Therapeutics, Inc., a biopharmaceutical company based in Delaware, filed a Form S-8 registration statement with the Securities and Exchange Commission (SEC). This filing pertains to the registration of additional shares for the company's 2022 Omnibus Equity Incentive Plan. The registration includes 276,368 additional shares of common stock, which are to be issued under the plan. This total comprises 114,286 shares approved by stockholders during the annual meeting on October 31, 2023, and 162,082 shares authorized under the Plan's Evergreen Provision, which automatically increases the number of shares available each year. The Plan's Evergreen Provision took effect on January 1, 2024, with the mentioned increase. The filing also references a 1-for-35 reverse stock split of the company's common stock, which took effect on December 4, 2023. As of February 13, 2024, ZyVersa Therapeutics had 4,631,987 shares of common stock outstanding. The Form S-8 incorporates by reference various financial documents, including the company's latest audited financial statements and quarterly reports, and details the indemnification provisions for directors and officers.
On February 14, 2024, ZyVersa Therapeutics, Inc., a biopharmaceutical company based in Delaware, filed a Form S-8 registration statement with the Securities and Exchange Commission (SEC). This filing pertains to the registration of additional shares for the company's 2022 Omnibus Equity Incentive Plan. The registration includes 276,368 additional shares of common stock, which are to be issued under the plan. This total comprises 114,286 shares approved by stockholders during the annual meeting on October 31, 2023, and 162,082 shares authorized under the Plan's Evergreen Provision, which automatically increases the number of shares available each year. The Plan's Evergreen Provision took effect on January 1, 2024, with the mentioned increase. The filing also references a 1-for-35 reverse stock split of the company's common stock, which took effect on December 4, 2023. As of February 13, 2024, ZyVersa Therapeutics had 4,631,987 shares of common stock outstanding. The Form S-8 incorporates by reference various financial documents, including the company's latest audited financial statements and quarterly reports, and details the indemnification provisions for directors and officers.
2024年2月14日，總部位於特拉華州的生物製藥公司ZyVersa Therapeutics, Inc. 向美國證券交易委員會（SEC）提交了S-8表格註冊聲明。該文件涉及公司2022年綜合股權激勵計劃的額外股份註冊。註冊包括276,368股額外的普通股，這些普通股將根據該計劃發行。該總數包括股東在2023年10月31日年會上批准的114,286股股票，以及根據該計劃的常青條款授權的162,082股股票，該條款自動增加每年的可用股票數量。該計劃的常青條款於2024年1月1日生效，上面提到的上調幅度。該文件還提到了對公司普通股進行1比35的反向股票拆分，該拆分於2023年12月4日生效。截至2024年2月13日，ZyVersa Therapeutics的已發行普通股爲4,631,987股。S-8表格以引用方式納入了各種財務文件，包括公司最新的經審計的財務報表和季度報告，並詳細說明了對董事和高級管理人員的賠償條款。
2024年2月14日，總部位於特拉華州的生物製藥公司ZyVersa Therapeutics, Inc. 向美國證券交易委員會（SEC）提交了S-8表格註冊聲明。該文件涉及公司2022年綜合股權激勵計劃的額外股份註冊。註冊包括276,368股額外的普通股，這些普通股將根據該計劃發行。該總數包括股東在2023年10月31日年會上批准的114,286股股票，以及根據該計劃的常青條款授權的162,082股股票，該條款自動增加每年的可用股票數量。該計劃的常青條款於2024年1月1日生效，上面提到的上調幅度。該文件還提到了對公司普通股進行1比35的反向股票拆分，該拆分於2023年12月4日生效。截至2024年2月13日，ZyVersa Therapeutics的已發行普通股爲4,631,987股。S-8表格以引用方式納入了各種財務文件，包括公司最新的經審計的財務報表和季度報告，並詳細說明了對董事和高級管理人員的賠償條款。
有用
沒用